SHC (Sotera Health Co) Beneish M-Score: -2.46 (As of Jun. 26, 2026)


SHC Sotera Health Co SHC
74 GF Score
Price $17.10
GF Value $16.31
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Sotera Health Co Beneish M-Score?

Sotera Health Co SHC +2.43% 74 Beneish M-Score is -2.46 as of Jun. 26, 2026. GuruFocus rates SHC with a GF Score™ of 74/100 and a GF Value™ of $16.31 (Fairly Valued). The stock has 3 warning signs investors should review. Among 195 Medical Diagnostics & Research companies, Sotera Health Co ranks worse than 64.1% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.46 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Sotera Health Co's Beneish M-Score or its related term are showing as below:

SHC' s Beneish M-Score Range Over the Past 10 Years
Min: -2.79   Med: -2.61   Max: -2.01
Current: -2.46

During the past 8 years, the highest Beneish M-Score of Sotera Health Co was -2.01. The lowest was -2.79. And the median was -2.61.


Sotera Health Co Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Sotera Health Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sotera Health Co Beneish M-Score Chart

Sotera Health Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial -2.72 -2.61 -2.01 -2.79 -2.61

Sotera Health Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.74 -2.67 -2.57 -2.61 -2.46

SHC vs BLLN, RDNT, TWST: Beneish M-Score Comparison

For the Diagnostics & Research subindustry, Sotera Health Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sotera Health Co Beneish M-Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Sotera Health Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Sotera Health Co's Beneish M-Score falls into.


SHC
74GF Score
Sotera Health Co SHC
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sotera Health Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Sotera Health Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0716+0.528 * 0.9983+0.404 * 0.9602+0.892 * 1.0744+0.115 * 1.3629
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.97+4.679 * -0.036165-0.327 * 0.9216
=-2.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was $176 Mil.
Revenue was 280.045 + 303.441 + 311.312 + 294.341 = $1,189 Mil.
Gross Profit was 147.069 + 165.92 + 177.561 + 166.621 = $657 Mil.
Total Current Assets was $586 Mil.
Total Assets was $3,236 Mil.
Property, Plant and Equipment(Net PPE) was $1,176 Mil.
Depreciation, Depletion and Amortization(DDA) was $127 Mil.
Selling, General, & Admin. Expense(SGA) was $258 Mil.
Total Current Liabilities was $208 Mil.
Long-Term Debt & Capital Lease Obligation was $2,247 Mil.
Net Income was 26.589 + 34.847 + 48.4 + 7.962 = $118 Mil.
Non Operating Income was 1.531 + 0.162 + 0.905 + -28.882 = $-26 Mil.
Cash Flow from Operations was 29.435 + 103.104 + 71.154 + 57.416 = $261 Mil.
Total Receivables was $153 Mil.
Revenue was 254.523 + 290.203 + 285.468 + 276.594 = $1,107 Mil.
Gross Profit was 135.432 + 164.365 + 158.024 + 152.791 = $611 Mil.
Total Current Assets was $555 Mil.
Total Assets was $3,098 Mil.
Property, Plant and Equipment(Net PPE) was $1,074 Mil.
Depreciation, Depletion and Amortization(DDA) was $164 Mil.
Selling, General, & Admin. Expense(SGA) was $247 Mil.
Total Current Liabilities was $226 Mil.
Long-Term Debt & Capital Lease Obligation was $2,324 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(176.322 / 1189.139) / (153.146 / 1106.788)
=0.148277 / 0.13837
=1.0716

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(610.612 / 1106.788) / (657.171 / 1189.139)
=0.551697 / 0.552644
=0.9983

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (585.971 + 1176.348) / 3235.898) / (1 - (554.99 + 1073.521) / 3097.528)
=0.455385 / 0.474255
=0.9602

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1189.139 / 1106.788
=1.0744

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(164.011 / (164.011 + 1073.521)) / (126.716 / (126.716 + 1176.348))
=0.132531 / 0.097245
=1.3629

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(257.912 / 1189.139) / (247.482 / 1106.788)
=0.21689 / 0.223604
=0.97

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((2246.909 + 207.804) / 3235.898) / ((2323.55 + 225.991) / 3097.528)
=0.758588 / 0.823089
=0.9216

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(117.798 - -26.284 - 261.109) / 3235.898
=-0.036165

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Sotera Health Co has a M-score of -2.46 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.46 mean?
Sotera Health Co (SHC) has a Beneish M-Score of -2.46 as of Jun. 26, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Sotera Health Co and its competitors. According to the industry distribution chart, Sotera Health Co ranks #125 out of 195 companies in the Medical Diagnostics & Research industry, placing it in the top 64.1%.
Is Sotera Health Co's Beneish M-Score too high?
Sotera Health Co's current Beneish M-Score is -2.46. Based on the distribution chart, Sotera Health Co ranks #125 out of 195 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Sotera Health Co has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sotera Health Co's Beneish M-Score compare to BLLN and RDNT?
According to the Medical Diagnostics & Research industry distribution chart, Sotera Health Co ranks #125 out of 195 companies for Beneish M-Score. This places Sotera Health Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Diagnostics & Research company?
A good Beneish M-Score depends on the Medical Diagnostics & Research industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Sotera Health Co and its competitors. Sotera Health Co's current Beneish M-Score is -2.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sotera Health Co stock overvalued right now?
Based on GuruFocus' analysis, Sotera Health Co (SHC) is currently considered Fairly Valued. The stock's GF Value™ is $16.31, compared to a current price of $17.10 — trading 4.8% above its estimated fair value. The current Beneish M-Score is -2.46. Sotera Health Co's overall GF Score™ is 74/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Sotera Health Co (SHC), the current Beneish M-Score is -2.46 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sotera Health Co (SHC) Overvalued in 2026?

Based on GuruFocus' analysis, Sotera Health Co stock appears to be overvalued. The current stock price of $17.10 is trading 4.8% above its estimated GF Value™ of $16.31. GuruFocus considers Sotera Health Co to be Fairly Valued.

Key valuation signals for SHC:

  • Beneish M-Score: -2.46
  • GF Value™: $16.31 vs. price of $17.10 (4.8% above fair value)
  • GF Score™: 74/100 with 3 warning signs

No single metric tells the full story. See the SHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sotera Health Co Business Description

Address 9100 South Hills Boulevard, Suite 300, Broadview Heights, OH, USA, 44147
Sotera Health Co provides sterilization, analytical lab testing, and advisory services to help ensure that medical, pharmaceutical, and food products are safe for healthcare practitioners, patients, and consumers. The company operates in three reportable segments: Sterigenics, Nordion, and Nelson Labs. The Sterigenics segment, which generates maximum revenue, provides outsourced terminal sterilization and irradiation services for medical devices, pharmaceuticals, food safety, and other application markets using three core technologies: gamma irradiation, EO processing, and E-beam irradiation. Geographically, the company generates maximum revenue from the United States, followed by Canada, Europe, and other regions.
74GF Score

Get the complete analysis for SHC

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.10
Price
$16.31
GF Value